Market Overview:
The global blood clotting accelerator market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of thrombotic disorders, rising demand for point-of-care testing, and technological advancements in the field of blood clotting accelerator products. Based on type, the global blood clotting accelerator market is segmented into powder and solution. The powder segment is expected to account for a larger share of the market in 2018 owing to its ease of use and low cost as compared to solutions. Based on application, the global blood clotting accelerator market is segmented into hospitals, specialty clinics, diagnostic laboratories, and research institutes. The hospitals segment accounted for a larger share of the market in 2017 due to rising demand for point-of-care testing in this sector.
Product Definition:
A blood clotting accelerator is a substance that speeds up the process of blood clotting. This can be important in medical procedures where it is necessary to stop bleeding quickly, or in cases of traumatic injury where a large amount of blood has been lost.
Powder:
Powder is a dry, granular material that contains anti-coagulant substances such as heparin and powdered sugar. It has the ability to dissolve easily in water or any other liquid and can be used directly for injection purposes. Powder is usually available in two forms namely powder for injection (PFI) and ready-to-use powder (RUP).
Solution:
Solution is a blood clotting agent that works by breaking down the coagulation factor in the blood. It helps to dissolve clots and prevent new ones from forming. The most common types of solutions are injections, tablets, and powder. They are available as both oral and injectable forms with different dosages depending on the indication for which they are used.
Application Insights:
The market is segmented based on the application of blood clotting accelerant, wherein hospitals held the largest share in 2017. The specialty clinics are estimated to be fastest-growing segment over the forecast period. Increasing cases of trauma and burn injuries coupled with rising geriatric population across the globe has led to a significant increase in demand for advanced therapeutics, thereby driving this segment growth.
Increasing cases of road accidents and increasing number of military personnel injured or disabled due to battlefield wounds have resulted in high demand for products that help accelerate wound healing & recovery process, which is further anticipated to drive product demand from 2018 to 2030. In addition, growing awareness regarding availability of advanced therapeutics along with rising incidences such as venous thromboembolism (VTE) & pulmonary embolism (PE) globally are expected fuel market growth over the forecast period.
Regional Analysis:
Europe dominated the global blood clotting accelerant market in terms of revenue share in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing R&D activities are some factors attributing to its large share. In addition, the growing aging population is expected to drive demand for accelerated products over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with an increase in medical tourism activities. Moreover, economic development has led to a rise in cardiovascular diseases (CVDs) cases which will further boost product demand across this region during the forecast period from 2018 to 2030 (USD X billion).
The U.S., China and Japan are among countries most affected by chronic venous insufficiency (CVI).
Growth Factors:
- Increasing incidence of blood clotting disorders
- Growing awareness about the benefits of blood clotting accelerant therapy
- Rising demand for minimally invasive procedures to treat blood clotting disorders
- Technological advancements in the field of blood clotting accelerant therapy
- increasing number of clinical trials evaluating the safety and efficacy of novel blood clotting accelerants
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood Clotting Accelerant Market Research Report
By Type
Powder, Solution
By Application
Hospitals, Specialty Clinics, Diagnostic Laboratories, Research Institutes
By Companies
Merck KgaA, Baxter International Inc, CSL Ltd., Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, PeproTech, Inc., ACROBiosystems
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Blood Clotting Accelerant Market Report Segments:
The global Blood Clotting Accelerant market is segmented on the basis of:
Types
Powder, Solution
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Diagnostic Laboratories, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck KgaA
- Baxter International Inc
- CSL Ltd., Inc.
- Grifols International SA
- Kedrion S.P.A.
- Novo Nordisk A/S
- Octapharma AG
- PeproTech, Inc.
- ACROBiosystems
Highlights of The Blood Clotting Accelerant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Solution
- By Application:
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood Clotting Accelerant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A blood clotting accelerator is a medication that helps to speed up the process of blood clotting. This can help to prevent serious injuries or death from occurring due to a bleed.
Some of the major players in the blood clotting accelerant market are Merck KgaA, Baxter International Inc, CSL Ltd., Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, PeproTech, Inc., ACROBiosystems.
The blood clotting accelerant market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Blood Clotting Accelerant Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Blood Clotting Accelerant Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Blood Clotting Accelerant Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Blood Clotting Accelerant Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Blood Clotting Accelerant Market Size & Forecast, 2018-2028
4.5.1 Blood Clotting Accelerant Market Size and Y-o-Y Growth
4.5.2 Blood Clotting Accelerant Market Absolute $ Opportunity
Chapter 5 Global Blood Clotting Accelerant Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Blood Clotting Accelerant Market Size Forecast by Type
5.2.1 Powder
5.2.2 Solution
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Blood Clotting Accelerant Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Blood Clotting Accelerant Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Diagnostic Laboratories
6.2.4 Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Blood Clotting Accelerant Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Blood Clotting Accelerant Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Blood Clotting Accelerant Analysis and Forecast
9.1 Introduction
9.2 North America Blood Clotting Accelerant Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Blood Clotting Accelerant Market Size Forecast by Type
9.6.1 Powder
9.6.2 Solution
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Blood Clotting Accelerant Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.10.3 Diagnostic Laboratories
9.10.4 Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Blood Clotting Accelerant Analysis and Forecast
10.1 Introduction
10.2 Europe Blood Clotting Accelerant Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Blood Clotting Accelerant Market Size Forecast by Type
10.6.1 Powder
10.6.2 Solution
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Blood Clotting Accelerant Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.10.3 Diagnostic Laboratories
10.10.4 Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Blood Clotting Accelerant Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Blood Clotting Accelerant Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Blood Clotting Accelerant Market Size Forecast by Type
11.6.1 Powder
11.6.2 Solution
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Blood Clotting Accelerant Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.10.3 Diagnostic Laboratories
11.10.4 Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Blood Clotting Accelerant Analysis and Forecast
12.1 Introduction
12.2 Latin America Blood Clotting Accelerant Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Blood Clotting Accelerant Market Size Forecast by Type
12.6.1 Powder
12.6.2 Solution
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Blood Clotting Accelerant Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.10.3 Diagnostic Laboratories
12.10.4 Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Blood Clotting Accelerant Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Blood Clotting Accelerant Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Blood Clotting Accelerant Market Size Forecast by Type
13.6.1 Powder
13.6.2 Solution
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Blood Clotting Accelerant Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.10.3 Diagnostic Laboratories
13.10.4 Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Blood Clotting Accelerant Market: Competitive Dashboard
14.2 Global Blood Clotting Accelerant Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck KgaA
14.3.2 Baxter International Inc
14.3.3 CSL Ltd., Inc.
14.3.4 Grifols International SA
14.3.5 Kedrion S.P.A.
14.3.6 Novo Nordisk A/S
14.3.7 Octapharma AG
14.3.8 PeproTech, Inc.
14.3.9 ACROBiosystems
